. 2024 Jun 4;12(6):615. doi: 10.3390/vaccines12060615

Table 2.

Effect of different bovine alphaherpesvirus (BoAHV) vaccine formulations on the neutralizing antibodies produced by guinea pigs (T0 and T30) and bovines (T0 and T60). Capital letters in the same column demonstrate differences between vaccines; lowercase letters on the same line demonstrate differences between times. Least significant difference test.

Vaccine	Guinea Pig—BoAHV-1 (Cooper)
Vaccine	T0	T30
Non-vaccinated	4.00 ± 0.00 ^A	4.00 ± 0.00 ^B
A	4.00 ± 0.00 ^A	4.00 ± 0.00 ^B
B	4.00 ± 0.00 ^Ab	36.0 ± 9.63 ^Aba
C	4.00 ± 0.00 ^Ab	6.85 ± 1.68 ^Ca
D	4.00 ± 0.00 ^Ab	53.33 ± 6.74 ^Aa
E	4.00 ± 0.00 ^A	4.00 ± 0.00 ^B
F	4.00 ± 0.00 ^Ab	8.66 ± 2.40 ^BCa
G	4.00 ± 0.00 ^A	4.00 ± 0.00 ^B
Vaccine	Bovine—BoAHV-1 (Cooper)
Vaccine	T0	T60
Non-vaccinated	4.00 ± 0.00 ^A	4.00 ± 0.00 ^B
B	4.00 ± 0.00 ^Ac	36.57 ± 7.58 ^Ba
D	4.00 ± 0.00 ^Ac	210.28 ± 57.09 ^Aa
H	4.00 ± 0.00 ^Ac	74.66 ± 14.11 ^Ba